RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Halozyme Therapeutics Stock

Halozyme Therapeutics EBIT 2024

Halozyme Therapeutics EBIT

518.31 M USD

Ticker

HALO

ISIN

US40637H1095

WKN

A0DLHS

In 2024, Halozyme Therapeutics's EBIT was 518.31 M USD, a 52.41% increase from the 340.07 M USD EBIT recorded in the previous year.

The Halozyme Therapeutics EBIT history

YEAREBIT (undefined USD)
2029e-
2028e1.18
2027e1.08
2026e0.86
2025e0.66
2024e0.52
20230.34
20220.29
20210.28
20200.14
2019-0.07
2018-0.07
20170.08
2016-0.08
2015-0.03
2014-0.06
2013-0.08
2012-0.05
2011-0.02
2010-0.05
2009-0.06
2008-0.05
2007-0.03
2006-0.02
2005-0.01
2004-0.01

Halozyme Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Halozyme Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Halozyme Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Halozyme Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Halozyme Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Halozyme Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Halozyme Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Halozyme Therapeutics’s growth potential.

Halozyme Therapeutics Revenue, EBIT and net profit per share

DateHalozyme Therapeutics RevenueHalozyme Therapeutics EBITHalozyme Therapeutics Net Income
2029e1.74 B undefined0 undefined1.11 B undefined
2028e1.78 B undefined1.18 B undefined1.1 B undefined
2027e1.67 B undefined1.08 B undefined1.01 B undefined
2026e1.42 B undefined856.74 M undefined810.85 M undefined
2025e1.17 B undefined659.66 M undefined619.08 M undefined
2024e1 B undefined518.31 M undefined512.03 M undefined
2023829.25 M undefined340.07 M undefined281.59 M undefined
2022660.1 M undefined289.4 M undefined202.1 M undefined
2021443.3 M undefined275.9 M undefined402.7 M undefined
2020267.6 M undefined144.3 M undefined129.1 M undefined
2019196 M undefined-67.6 M undefined-72.2 M undefined
2018151.9 M undefined-69.3 M undefined-80.3 M undefined
2017316.6 M undefined81 M undefined63 M undefined
2016146.7 M undefined-83.2 M undefined-103 M undefined
2015135.1 M undefined-27.5 M undefined-32.2 M undefined
201475.3 M undefined-63 M undefined-68.4 M undefined
201354.8 M undefined-80.4 M undefined-83.5 M undefined
201242.3 M undefined-53.6 M undefined-53.6 M undefined
201156.1 M undefined-18.5 M undefined-19.8 M undefined
201013.6 M undefined-53 M undefined-53.2 M undefined
200913.7 M undefined-58.5 M undefined-58.4 M undefined
20088.8 M undefined-50.4 M undefined-48.7 M undefined
20073.8 M undefined-28.1 M undefined-23.9 M undefined
20061 M undefined-15.6 M undefined-14.8 M undefined
2005100,000 undefined-13.6 M undefined-13.3 M undefined
20040 undefined-9.1 M undefined-9.1 M undefined

Halozyme Therapeutics stock margins

The Halozyme Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Halozyme Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Halozyme Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Halozyme Therapeutics's sales revenue. A higher gross margin percentage indicates that the Halozyme Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Halozyme Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Halozyme Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Halozyme Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Halozyme Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Halozyme Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Halozyme Therapeutics Margin History

Halozyme Therapeutics Gross marginHalozyme Therapeutics Profit marginHalozyme Therapeutics EBIT marginHalozyme Therapeutics Profit margin
2029e76.8 %0 %63.51 %
2028e76.8 %66.44 %61.66 %
2027e76.8 %64.55 %60.66 %
2026e76.8 %60.16 %56.94 %
2025e76.8 %56.53 %53.05 %
2024e76.8 %51.62 %51 %
202376.8 %41.01 %33.96 %
202278.9 %43.84 %30.62 %
202181.64 %62.24 %90.84 %
202083.78 %53.92 %48.24 %
201976.73 %-34.49 %-36.84 %
201893.29 %-45.62 %-52.86 %
201790.18 %25.58 %19.9 %
201677.37 %-56.71 %-70.21 %
201578.31 %-20.36 %-23.83 %
201469.85 %-83.67 %-90.84 %
201388.69 %-146.72 %-152.37 %
201297.4 %-126.71 %-126.71 %
201199.47 %-32.98 %-35.29 %
201092.65 %-389.71 %-391.18 %
200997.81 %-427.01 %-426.28 %
200895.45 %-572.73 %-553.41 %
200794.74 %-739.47 %-628.95 %
200650 %-1,560 %-1,480 %
2005100 %-13,600 %-13,300 %
200476.8 %0 %0 %

Halozyme Therapeutics Aktienanalyse

What does Halozyme Therapeutics do?

Halozyme Therapeutics Inc is a biotechnology company based in San Diego, California, specializing in the development of therapies for cancer and rare diseases. The company was founded in 1998 and has been listed on the NASDAQ since 2004. The business model of Halozyme is based on the use of the enzyme hyaluronidase, which helps distribute medications more quickly and effectively in the body. By using hyaluronidase, the absorption of medications can be improved, increasing their effectiveness and improving patient treatment. The company operates in three different areas: the first area is the development of its own therapies based on the use of hyaluronidase. Halozyme has several medications in the pipeline, including a therapy for pancreatic cancer and a treatment for muscular dystrophy. The second area is partnering with other pharmaceutical companies to enable faster absorption of their medications through the use of hyaluronidase. Halozyme has entered into over 30 partnerships with companies such as Pfizer, Roche, and Janssen. The third area is the development of diagnostic tools based on the analysis of protein-protein interactions. This technology is intended to accelerate the drug development process and support the selection of the most promising candidates. An example of a product developed by Halozyme in collaboration with a partner company is Herceptin SC (subcutaneous). Herceptin is a medication for the treatment of breast cancer that is typically administered intravenously. However, by adding hyaluronidase, the medication can also be administered subcutaneously, reducing treatment duration and patient burden. Halozyme aims to develop innovative therapies and accelerate the drug development process. By using hyaluronidase and partnering with other companies, the company can contribute to improving the effectiveness of medications and optimizing treatment outcomes for patients. Halozyme Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Halozyme Therapeutics's EBIT

Halozyme Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Halozyme Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Halozyme Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Halozyme Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Halozyme Therapeutics stock

How much did Halozyme Therapeutics achieve in EBIT for the current year?

In the current year, Halozyme Therapeutics has achieved an EBIT of 518.31 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Halozyme Therapeutics.

How has the EBIT of Halozyme Therapeutics developed in recent years?

The EBIT of Halozyme Therapeutics has increased by 52.411% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Halozyme Therapeutics?

The EBIT of Halozyme Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Halozyme Therapeutics pay?

Over the past 12 months, Halozyme Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Halozyme Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Halozyme Therapeutics?

The current dividend yield of Halozyme Therapeutics is .

When does Halozyme Therapeutics pay dividends?

Halozyme Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Halozyme Therapeutics?

Halozyme Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Halozyme Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Halozyme Therapeutics located?

Halozyme Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Halozyme Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Halozyme Therapeutics from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Halozyme Therapeutics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Halozyme Therapeutics in the year 2023?

In the year 2023, Halozyme Therapeutics distributed 0 USD as dividends.

In which currency does Halozyme Therapeutics pay out the dividend?

The dividends of Halozyme Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Halozyme Therapeutics

Our stock analysis for Halozyme Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Halozyme Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.